Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 12, 2002 - Issue 7
Submit an article Journal homepage
83
Views
38
CrossRef citations to date
0
Altmetric
Miscellaneous

New inhibitors of poly(ADP-ribose) polymerase and their potential therapeutic targets

Cristina Cosi Neurobiology II Division, Pierre Fabre Research Center, 17 ave Jean Moulin, 81106 Castres France, Tel: +33 5 6371 4286; Fax: +33 5 6371 4363;, E-mail: [email protected]
Pages 1047-1071 | Published online: 25 Feb 2005

Bibliography

  • CHAMBON P, WEILL JD, MANDEL P: Nicotinamide mononucleotide activation of new DNA-dependent polyadenylic acid synthesizing nuclear enzyme. Biochem. Biophys. Res. Commun. (1963) 11:39–43.
  • SHALL S, DE MURCIA G: Poly(ADP-ribose) polymerase-1: what have we learned from the deficient mouse model? Mutation Res. (2000) 460:1-15.
  • PURNELL MR, WHISH WJD: Novel inhibitors of poly(ADP-ribose) synthetase. Biochem. J. (1980) 185:775–777.
  • SEBOLT-LEOPOLD JS, SCAVONE SV: Enhancement of alkylating agent activity in vitro by PD 128763, a potent poly(ADP-ribose)synthetase inhibitor. Int. I Radiat. Oricol Biol. Phys. (1992) 22:619–621.
  • BOWMAN KJ, NEWELL DR, CALVERT AH, CURTIN NJ: Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro. Br. J. Cancer (2001) 84:106–112.
  • MAZZON E, SERRAINO I, LI J-H et al: GPI 6150, a poly(ADP-ribose)polymerase inhibitor, exhibits an anti-inflammatory effect in rat models of inflammation. Eur. Pharmacol (2001) 85–94.
  • ABDELKARIM GE, GERTZ K, HARMS C etal.: Protective effects of PJ34, a novel, potent inhibitor of poly(ADP-ribose)-polymerase (PARP) in in vitro and in vivo models of stroke. Irk j Mal Med. (2001) 7:255–260.
  • DE MURCIA G, HULETSKY A, LAMARRE D et al.: Modulation of chromatin superstructure induced poly (ADP-ribose) synthesis and degradation. Biol. Chem. (1986) 261:7011–7017.
  • AMSTAND AP, KRUPITZA G, CERUTTIAP: Mechanism of c- los induction by active oxygen. Cancer Res. (1992) 52:3952–3960.
  • DEMURCIA G, MENISSER DEMURCIA J: Poly (ADP-ribose) polymerase: a molecular nick-sensor. TIBS (1994) 19:172–176.
  • KAMESHITA I, MATSUDA M, NISHIKIMI M, USHIRO H, SHIZUTA Y: Reconstitution and poly (ADP-ribosyflation of proteolytically fragmented poly(ADP-ribose) synthetase J. Biol. Chem. (1986) 261:3863–3868.
  • IKEJIMA M, NOGUCHI S, YAMASHITAR et al.: The zinc fingers of human poly (ADP-ribose) polymerase are differentially required for the recognition of DNA breaks and nicks and consequent enzyme activation. J Biol. Chem. (1990) 265:21907–21913.
  • BAUER PI, BUKI KG, KUN E: Macromolecular association of ADP-ribosykransferase and its correlation with enzymatic activity. Biochem. j (1990) 270:17–26.
  • UCHIDA K, HANAI S, ISHIKAWA K et al.: Cloning of a cDNA encoding Drosophila poly(ADP-ribose) polymerase: leucine zipper in the auto-modification domain. Proc. Natl. Acad. Sri. USA (1993) 90:3481–3485.
  • MENDOZA-ALVAREZ H, ALVAREZ-GONZALES R: Poly(ADP-ribose) polymerase is a catalytic dimer and the automodification reaction is intermolecular. Biol. Chem. (1993) 268:22575–22580.
  • BUM KG, BAUER PI, HAKAM A, KUN E: Identification of domains of poly (ADP-ribose) polymerase for protein binding and self-association. j Biol. Chem. (1995) 270:3370–3377.
  • RUF A, MENISSER DE MURCIA J, DE MURCIA GM, SCHULZ EG: Structure of the catalytic fragment of poly(ADP-ribose) polymerase from chicken. Proc. Natl. Acad. Sci. USA (1996) 93:7481–7485.
  • GRIFFIN RJ, CURTIN NJ, NEWELL DR, GOLDING BT, DURKACZ BW, CALVERT AH: The role of inhibitors of poly(ADP-ribose)polymerase as resistance-modifying agents in cancer therapy. Biochimie (1995) 77:408–422.
  • JACOBSON MK, JACOBSON EL: Discovering new ADP-ribose polymer cycles: protecting the genome and more. Trends Biochem.Sci. (1999) 24:415–417.
  • SMITH S: The world according to PARP. Trends Biochem. Sci. (2001) 26:174–179.
  • SALLMANN RF, VODENICHAROV DM, WANG Z-QI, POIRIER GG: Characterization of sPARP-1. j Biol. Chem. (2000) 275:15504–15511.
  • BABIYCHUK E, COTTRILL PB, STOROZHENKO S et al: Higher plants posses two structurally different poly(ADP-ribose)polymerases. Plant j (1998) 15:635–645.
  • AME J, ROLLI V, SCHREIBER V et al: PARP-2, a novel mammalian DNA damage-dependent poly(ADP-ribose)polymerase. Biol. Chem. (1999) 274:17860–17868.
  • BERGHAMMER H, EBNER M, MARKSTEINER,R, AUER B: pADPRT-2: A novel mammalian polymerizing(ADP-ribosyl-)transferase gene related to truncated pADPRT homologues in plants and Caenorhabditis elegans. FEBS Lett. (1999) 449:259–263.
  • JOHANSSON M: A human poly(ADP-ribose) polymerase gene family (ADPRTL): cDNA cloning of two novel poly(ADP-ribose) polymerase homologues. Cerromics (1999) 57:442–445.
  • KICKHOEFER VA, SIVA AC, KEDERSHA NL etal.: The 193-kD vault protein, VPARP, is a novel poly(ADP-ribose) polymerase. J. Cell Biol. (1999) 146:917–928.
  • SMITH S, GIRIAT I, DE LANGE T: Tankyrase a poly(ADP-ribose)polymerase at human telomers. Science (1998) 282:1484–1487.
  • CHONG L, VAN STEENSEL B, BROCCOLI D et al A human telomeric protein. Science (1995) 270:1663–1667.
  • VAN STEENSEL B, SMOGORZEWSKA A, DE LANGE T: TRF2 protects human telomeres from end-to-end fusions. Cell (1998) 92:401–413.
  • VAN STEENSEL B, DE LANGE T: Control of telomere length by the human telomeric protein TRF1. Nature (1997) 385:740–743.
  • SMITH S, DE LANGE T: Tankyrase promotes telomere elongation in human cells. Curr. Biol. (2000) 10:1299–302.
  • ADP-ribosylation of proteins: enzymology and biological significance. Molecular biology biochemistry and biophysics vol 37 Althaus FR, Richer C (Eds), Springer-Verlag, New York (1987)
  • ELIASSON MJ, SAMPEI K, MANDIR AS: Poly(ADP-ribose)polymerase gene disruption renders mice resistant to cerebral ischemia. Nat. Med. (1997) 3:1089–1095.
  • SZABO C: Role of poly(ADP-ribose) synthethase in inflammation. Eur. Pharmacol. (1998) 350(1):1–19.
  • SHARP C, WARREN A, OSHIMA T et al.: Poly ADP ribose-polymerase inhibitors prevent the upregulation of ICAM-1 and E-selectin in response to Thl cytokine stimulation. Inflammation (2001) 25:157–163.
  • ULLRICH O, DIESTEL A, EYLIPOGLU YI, NITSCH R: Regulation of microglia expression of integrins by poly(ADP-ribose) polymerase-1. Nat. Cell Biol. 3:1035-1042.
  • HASSA PO, COVIC M, HASAN S et al.: The enzymatic and DNA binding activity of PARP-1 are not required for NF-icB coactivator function. j Biol. Chem. (2001) 276:45588–45597.
  • PARP as a therapeutic target. Zhang J (Ed.),CRC Press, Boca Raton, London, New York, Washington DC (2001).
  • CARSON DA, SETO S, WASSON DB, CARRERA CJ: DNA strand breaks, NAD metabolism, and programmed cell death. Esp. Cell Res. (1986) 164:273–281.
  • JUAREZ-SALINAS H, SIMS JL, JACOBSON MK: Poly (ADP-ribose) levels in carcinogen-treated cells. Nature (1979) 282:740–741.
  • YOSHIHARA K, ITAYA A, TANAKA Y et al.: Poly(ADP-ribos)ylation of nuclear enzymes. In: ADP-ribosylation of proteins. Althaus FR, Hiltz H, Shall S (Eds), (1985) Springer-Verlag Berlin, Heidelberg.
  • LINDAHL T, SATOH MS, POIRIER GG, KLUNGLAND A: Post-translational modification of poly(ADP-ribose)-polymerase induced by DNA strand breaks. TIBS (1995) 20:405–411.
  • DANTZER F, NASHEUER H, VONESCH J etal.: Functional association of poly(ADP-ribose)polymerase with DNA polymerase a-primase complex: a link between DNA strand-break detection and DNA replication. Nucleic Acids Res. (1998) 26:1891–1898.
  • DURKACZ BW, OMIDIJI O, GRY DA, SHALL S: (ADP-ribose)n synthesis participates in DNA excision repair. Nature (1980) 283:593–596.
  • BURKLE A, CHEN G, KUPPER JH, GRUBE K, ZELLER WJ: increased poly(ADP-ribosyfiation in intact cells by cisplatin treatment. Carcirrogerresis (1993) 14:559–561.
  • CHATERJEE S, TRIVEDI D, PETZOLD SJ, BERGER NA: Mechanisms of epipodophyllotoxin-induced cell death in poly(adenosine diphosphate-ribose) synthesis-deficient V79 Chinese hamster cell lines. Cancer Res. (1990) 50:2713–2718.
  • AUGUST EM, COOPER DL, PRUSOFF WH: Inhibition of poly(adenosine diphosphate ribose) polymerase by thymidine and thymidine analogues inL1210 cells and its relationship to the potentiation of the antitumor activity of 1,3-bis(2-chloroethyl)-1-nitrosourea but not of 3'43- (2-chloroethyl)-3-nitrosoureidol-3'-deoxythymidine. Cancer Res. (1991) 51:1586–1590.
  • STIERUM RH, VAN HERWIEN MHM, HAGEMAN GJ, KLEINJANS JCS: Increase poly(ADP-ribose)polymerase activity during repair of(±)- antibenzo hal pyrene diolepoxide-induced DNA damage in human peripheral blood lymphocytes in vitro. Carcinogenesis (1994) 15:745–751.
  • HUET J, LAVAL F: Potentiation of cell killing by inhibitors of poly(adenosine diphosphate ribose) synthesis in bleomycin-treated Chinese hamster ovary cells. Cancer Res. (1985) 45:987–991.
  • BEN-HUR E, CHEN CC, ELKIND MM: Inhibitors of poly(adenosine diphosphoribose) synthetase, examination of metabolic perturbations and enhancement of radiation response in Chinese hamster cells. Cancer Res. (1985) 45:2123–2127.
  • SHALL S: ADP-ribose in DNA repair: a new concept of excision repair. Adv. Radiat. Biol. (1984) 11:1–69.
  • CLEAVER JE: Differential toxicity of 3-aminobenzamide to wild-type and 6-thioguanine resistant CHO cells by interference with pathways of purine biosynthesis. Mutation Res. (1984) 131:123–127.
  • HOLL V, COELHO D, WELTIN D et al.:Modulation of antiproliferative activity of anticancer drugs in hematopoietic tumor cell lines by the poly(ADP-ribose)-polymerase inhibitor 6 (5H) - phenanthridinone. Anticancer Res. (2000) 20:3233–3241.
  • WITMER MA, ABOUL-ELA N, JACOBSON MK, STAMATO TD: Increased sensitivity to DNA-alkylating agents in CHO mutants with decreased poly(ADP-ribose)polymerase activity. Mutation Res. (1994) 314:249–260.
  • DELANEY CA, WANG LZ, KYLE S: Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose)polymerase inhibitors in a panel of human tumor cell lines. Clin Cancer Res. (2000) 6:2860–2867.
  • KATO T, SUZUMURA Y, FUKUSHIMA M: Enhancement of bleomycin activity by 3-aminobenzamide, a poly (ADP-ribose) synthesis inhibitor, in vitro and in vivo. Anticancer. Res. (1988) 8:239–244.
  • CHEN G, PAN QC: Potentiation of antitumor activity of cisplatin in mice by 3-aminobenzamide. Cancer Chemother. Pharmacol. (1988) 22:303–307.
  • PETROU C, MOURELATOS D, MIOGLOU E, DOZI-VASSILIADIS J, CATSOULACOS P: Effects of alkylating antineoplastics alone or in combination with 3-aminobenzamide on genotoxicity, antitumor activity, and NAD levels in human lymphocytes in vitro and in Ehrlich ascites tumor cells in vivo. Teratogenesis Carcinog. Mutagen. (1990) 10:321–331.
  • HORSMAN MR, BROWN DM, LEMMON MJ, BROWN JM, LEE WW: Preferential radiosensitization by analogues of nicotinamide and benzamide. Radiation Oncol. Biol. Phys. (1986) 12:1307–1310.
  • SCHRAUFSTATTER IU, HYSLOP PA, HINSHAW DB etal.: Hydrogen peroxide-induced injury of cells and its prevention by inhibitors of poly(ADP-ribose) polymerase. Proc. Nati Acad. Sci. USA (1986) 83:4908–4912.
  • GRANCVIST K, MARKLUND SL, TALLEDAL TB: CuZn-superoxide dismutase, Mn-superoxide dismutase, catalase and glutathione peroxidase in pancreatic islets and other tissues in the mouse. Biochem. J (1981) 199:393–398.
  • MALAISSE WJ, MALAISSE-LAGAE F, SENER A, PIPELEERS DG: Determinants of the selective toxicity of alloxan to the pancreatic B cell. Proc. Nati Acad. Sci. USA (1982) 79:927–930.
  • RABINOVITCH A: Free radicals as mediators of pancreatic islets beta-cell injury in autoimmune diabetes (editorial; comment) j Lab. Clin. Med. (1992) 119:455–456.
  • WU G, MARLISS EB: Enhanced glucosemetabolism and respiratory burst in peritoneal macrophages from spontaneusly diabetic BB rats. Diabetes (1993) 42:520–529.
  • CORBETT JA, MIKHAEL A, SHIMIZU J et al.: Nitric oxide production in islet from non-obese diabetic mice: aminoguanidine-sensitive and -resistant stages in the immunological diabetic process. Proc. Natl. Acad. Sci USA (1993) 90:8992–8995.
  • WELSH N, SANDLER S: Interleukin-1 beta induces nitric oxide production and inhibits the activity of aconitase without decreasing glucose oxidation rates in isolated mouse pancreatic islets. Biochem. Biophys. Res. Commun. (1992) 182:333–340.
  • MOLINA Y VEDIA L, McDONALD B et al.: Nitric oxide-induced s-nitrosylation of glyceraldehyde-3-phosphete dehydrogenase inhibits enzymatic activity and increases endogenous ADP-ribosylation j Biol. Chem. (1992) 267:24929-24932 (Erratum Biol. Chem. (1993) 268:3016).
  • RADONS J, HELLER B, BORKLE A et al.: Nitric oxide toxicity in islet cells involves poly(ADP-ribose)polymerase activation and concomitant NAD± depletion. Biochem. Biophys. Res. Commun. (1994) 199:1270–1277.
  • KALLMANN B, BURKART V, KRONCKE KD, KOLB-BACHOFEN V, KOLB H: Toxicity of chemically generated nitric oxide towards pancreatic islet cells can be prevented by nicotinamide. Life Li. (1992) 51:671–678.
  • FEHSEL K, JALOWY A, SUN Q, BURKART V, HARTMANN B, KOLB H: Islet cell DNA is a target of inflammatory attack by nitric oxide. Diabetes (1993) 42:496–500.
  • HELLER B, BORKLE A, RADONS J et at: Analysis of oxygen radical toxicity in pancreatic islets at the single cell level. Biol. Chem. (1994) 375:597–602.
  • HELLER B, WANG ZQ, WAGNER EF et al.: Inactivation of the poly(ADP-ribose) polymerase gene affects oxygen radical and nitric oxide toxicity in islet cells. _J. Biol. Chem. (1995) 270:11176–11180.
  • YONEMURA Y, TAKASHIMA T, MIWA K, MIYAZAKI I, YAMAMOTO H, OKAMOTO H: Amelioration of diabetes mellitus in partially depacreatinized rats by poly(ADP-ribose) synthetase inhibitors, evidence for islet I3-cell regeneration. Diabetes (1984) 33:401–404.
  • YAMADA K, NONAKA K, HANFUSA T, MIYAZAKI A, TOYOSHIMA H, TARUI S: Preventive and therapeutic effects of large doses of nicotinamide injections on diabetes associated with insulinitis. Diabetes (1982) 31:749–753.
  • HALLIWELL B, GUTTERIDGE JMC: The importance of free radicals and catalytic metal ions in human disease. Mol. Aspects Med. (1985) 8:89–193.
  • LED OUX SP, HALL CR, FORBES PM,PATTON NJ, WILSON GL: Mechanisms of nicotinamide and thymidine protection from alloxan and streptozotocin toxicity. Diabetes (1988) 37:1015–1019.
  • HENNING SM, MCKEE RW, SWENDSEID ME: Hepatic content of s-adenosylmethionine, S-adenosylhomocysteine and glutathione in rats receiving treatments modulating methyl donor availability. J. Num (1989) 119:1478–1482.
  • KANG-LEE YAE, MCKEE RW, WRIGHT SM, SWENDSEID ME, JENDEN DJ, JOPE RS: Metabolic effects of nicotinamide administration in rats. J. Num (1993) 113:215–221.
  • HENNING SM, MCKEE RW, SWENDSEID ME: Hepatic poly(ADP-ribose)polymerase activity in methyl donor-deficient rats. J. Num. (1989b) 119:1528–1531.
  • ELLIOT RB, CHASE HP: Prevention or delay of Type I (insulin-dependent) diabetes mellitus in children using nicotinamide. Diabetologia (1991) 34:362–365.
  • BURKAT V, WANG ZQ, RADONS J et al.: Mice lacking of the poly(ADP-ribose) polymerase gene are resistant to pancreatic beta-cell destruction and diabetes development induced by streptozotocin. Nat. Med. (1999) 5:314–319.
  • MASUTANI M, SUZUKI H, KAMADA N et al.: Poly(ADP-ribose) polymerase gene disruption conferred mice resistance to streptozotocin-induced diabetes. Proc. Nati Acad. Sri. USA (1999) 96:2301–2304.
  • PIEPER AA, BRAT DJ, KRUG DK: Poly(ADP-polymerase) deficient mice are protected from streptozotocin-induced diabetes. Proc. Nati Acad. Sci. USA (1999) 96:3059–3064.
  • ZINGARELLI B, SALZMAN LA, SZABO C: Protective effects of nicotinamide against nitric oxide-mediated delayed vascular failure in endotoxic shock: potential involvement of polyADP ribosyl synthetase. Shock (1996) 5:258–264.
  • SZABO C, ZINGARELLY B, SALZMAN A: Role of poly-ADP ribosykransferase activation in the vascular contractile and energetic failure elicited by exogenous and endogenous nitric oxide and peroxynitrite. Circ. Res. (1996) 78:1051–1063.
  • SZABO C, CUZZOCREA S, ZINGARELLI B et al.: Endothelial dysfunction in a rat model of endotoxic shock: importance of the activation of poly(ADP-ribose) synthetase by peroxynitrite. j Clin. Invest. (1997) 100:723–735.
  • SZABO C, LIM LH, CUZZOCREA S et al.: Inhibition of poly(ADP-ribose)synthetase attenuates neutrophil recruitment and exerts anti-inflammatory effects. J. Esp. Med. (1997) 1041–1049.
  • OLIVER FJ, MENISSER-DE MURCIA J, NACCI C et al.: Resistance to endotoxic shock as a consequence of defective NF-icB activation in poly (ADP-ribose) polymerase-1 deficient mice. EMBO J. (1999) 18:4446–4454.
  • THIEMERMANN C, WAYMAN N, McDONALD CM etal.: PARP inhibitors and cardioporotection. In: PARP as a therapeutic target. Zhang J (Ed), CRC Press, Boca Raton, London, New York, Washington DC (2001):117–133.
  • HYO CHOL HA, SNYDER HS: Poly(ADP-ribose) polymerase-1 in the nervous system. Neurobiol. Dis. (2000) 7:225–239.
  • COSI C, SUZUKI H, FACCI L, MILANI D, SKAPER SD: Poly(ADP-ribose)-polymerase: an early marker of glutamate mediated neuronal death. Soc. Neurosci. Abstr. USA (1992) 18:46.
  • COSI C, SUZUKI H, MILANI D et al.: Poly(ADP-ribose) polymerase: early involvement in glutamate-induced neurotoxicity in cultured cerebellar granule cells. J. Neurosci. Res. (1994) 39:38–46.
  • ZHANG J, DAWSON VL, DAWSON TM SNYDER SH: Nitric oxide activation of poly(ADP-ribose)synthetase in neurotoxicity. Science (1994) 263:687–689.
  • ZHANG J, PIEPER A, SNYDER SH: Poly(ADP-ribose)synthetase activation: an early indicator of neurotoxic DNA damage. J.Neurochem. (1995) 65:1411–1414.
  • SHENG P, CERRUTI C, CADET JL: Methamphetamine (METH) causes reactive gliosis in vitro :attenuation by the poly(ADPribose) polymerase, benzamide. Pharmacol. Lett. (1994) 55:PL51-PL54.
  • COSI C, COLPAERT F, KOEK W, DEGRYSE A, MARTEN M: Poly(ADP-ribose)polymerase inhibitors protect against MPTP-induced depletions of striatal dopamine and cortical noradrenaline in C57B1/6 mice. Brain Res. (1996) 729:264–269.
  • COSI C, SUZUKI H, SKAPER SD et al.:Poly(ADP-ribose)polymerase (PARP) revisited. A new role for an old enzyme: PARP involvement in neurodegeneration and PARP inhibitors as possible neuroprotective agents. Annals. NY Acad. Sci (1997) 825:366–379.
  • BANASIK M, KOMURA H, SHIMOYAMA M, UEDA K: Specific inhibitors of poly(ADP-ribose)synthetase and mono (ADP-ribosyl)ransferase. J. Biol. Chem. (1992) 267:1569–1575.
  • COSI C, MARTEN M: Decrease in mousebrain NAD± and ATP induced by 1-methyl-4-phenyl-1 2,3,6-tetrhydropyridine (MPTP): prevention by the poly(ADP-ribose)polymerase inhibitor, benzamide. Brain Res. (1998) 809:58-67. mo.
  • COSI C, CHOPIN P, MARTEN M: Benzamide, an inhibitor of poly(ADP-ribose)polymerase attenuates methamphetamine-induced dopamine neurotoxicity in the C57B1/6N mouse. Brain Res. (1996) 735:343–348.
  • MANDIR AS, PRZEDBORSKI S, JACKSON-LEWIS etal.: Poly(ADP-ribose) polymerase activation mediates 1-methy1-4-pheny1-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism. Proc. Natl. Acad. Li. (1999) 96:5774–5779.
  • COSI C, CAVALIERI E, CARCERERI DE PRATT A et al.: Effects of kainic acid lesioning on poly(ADP-ribose) polymerase (PARP) activity in the rat striatum in vivo. Amino Acids (2000) 19:229–237.
  • CHOL HA H, HESTER DL, SNYDER HS: Poly(ADP-ribose) polymerase-1 dependence of stress-induced transcription factors and associated gene expression in glia. Proc. Natl. Acad. Sci. USA (2002) 99:3270–3275.
  • TJIAN R, MANIATIS T: Transcriptional activation: a complex puzzle with few easy pieces. Cell (1994) 77:5–8.
  • CERVELLERA MN, SALA A: Poly(ADP-ribose)polymerase is a B-MYB coactivator. J.Biol. Chem. (2000) 275:10692–10696.
  • KROGER H, MIESEL R, DIETRICH A, OHDE M, RAJNAVOLGYI E, OCKENFELS H: Synergistic effect of thalidomide and poly(ADP-ribose)polymerase inhibition Type II collagen-induced arthritis in mice. Inflammation (1996) 20:203–215.
  • HAUSCHILDT S, SCHEIPERS P, BESSLER WG et al.: Inhibition of poly(ADP-ribose)polymerase suppress lipopolysaccharide-induced nitric oxide formation in macrophages. Biochem. Biophys. Res. Commun. (1991) 179:865-871. ma. HAUSCHILDT P, SCHEIPERS WG, BESSELER A et al.: Induction of nitric oxide synthase in L929 cells by tumor-necrosis factor alpha is prevented by inhibition of poly(ADP-ribose)polymerase. Biochem. J. (1992) 288:255–600.
  • PELLAT-DECEUNYNGK C, WIETZERBIN J, DRAPIER JC: Nicotinamide inhibits nitric oxide synthase mRNA in activated macrophages. Biochem. (1994) 297:53–58.
  • LE PAGE C, PELLAT-DECEUNYNCK C, DRAPIER JC et al.: Effects of inhibitors of ADP-ribosylation on macrophage activation. Adv. Esp. Med. Biol. (1997) 419:203–207.
  • LE PAGE C, SANCEAU J, DRAPIER JC et al.:Inhibitors of ADP-ribosylation impair inducible nitric oxide synthase gene transcription through inhibition of NFicB activation. Biochem. Biophys. Res. Commun. (1998) 243:451–457.
  • BERTON C, LAUDANNA C: Activation of human monocyte-derived macrophages by interferon gamma is accompanied by increase of poly(ADP-ribose)polymerase activity. Biochem. Biophys Acta. (1991) 1091:101–109.
  • MANDIR SA, POITRAS FM, BERLINER RA et al.: NMDA but non-NMDA excitotoxicity is mediated by poly(ADP-ribose) polymerase. j Neurosci. (2000) 20(21):8005–8011.
  • SUTO MJ, TURNER WR, ARUNDEL-SUTO CM, WERBEL LM, SEBOLT-LEOPOLD JS: Dihydroisoquinolines: the design and the synthesis of a new series of potent inhibitors of poly(ADP-ribose)polymerase. Anticancer Drug Des. (1991) 7:101–117.
  • CLARK JB, FERRIS JM, PINDER S: Inhibition of nuclear NAD nucleoside and poly ADP-ribose polymerase activity from rat liver by nicotinamide and 5-methyl-nicotinamide. Biochem. Biophys. Acta (1971) 238:82–85.
  • KIDWELL WRN, STONE PR: Variations in poly (ADP-ribose) and poly (ADP-ribose) synthetase in synchronously dividing cells. In: ADP-ribosylation Reaction: Biology and Medicine. Hayaishi O, Ueda K (Ed.), Academic Press, Inc. New York. (1982):373–388
  • BREDEHORST R, LENGYEL H, HILZ H et al.: Increase of mono (ADP-ribose)protein conjugate levels in rat liver induced by nicotinamide administration. Hoppe SeylersZ Physic] Chem. (1980) 361:559–562.
  • APSIMON MM, RAWLING JM, KIRKLAND JB: Nicotinamide megadosing increases hepatic poly(ADP-ribose) levels in choline-deficient rats. j Num. (1995) 125:1826–1832.
  • SHALL S: Experimental manipulation of the specific activity of poly (ADP-ribose)-polymerase. j Biochem. (1975) 77:2.
  • SIMS JL, SIKORSKI GW, CATINO DM, BERGER SJ, BERGER NA: Poly(adenosinediphosphoribose) polymerase inhibitors stimulate unscheduled deoxyribonucleic acid synthesis in normal human lymphocytes. Biochemistry (1982) 21:1813–1821.
  • MOSES K, HARRIS AL, DURKAZ BW: Adenosine-diphosphoribosykransferase inhibitors can protect against or potentiate the cytotoxicity of S-phase acting drugs. Biochem. Pharmacol (1988) 37:2155–2160.
  • MILANI MK, CLEAVER EJ: Inhibitors of poly (adenosine diphosphate-ribose) synthesis: effect on other metabolic processes. Science (1984) 223:589–591.
  • JOHNSON GS: Benzamide and its derivatives inhibit nicotinamide methylation as well as ADP-ribosylation. Biochem. Int. (1981) 2:611–617.
  • RANKIN PW, JACOBSON EL, BENJAMINS RC, MOSS J, JACOBSON MK: Quantitative studies of inhibitors of ADP-ribosylation in vitro and in vivo. Biol. Chem. (1989) 264:4312–4317.
  • MILLER MS, ZOBRE C, LEWIS M: In vitro neuroprotective activity of inhibitors of poly-ADP-ribose polymerase. Soc. Neurosci. Abstr. USA (1993) 19:1656.
  • SHAH MG, POIRIER D, DESNOYERS S et al: Complete inhibition of poly(ADP-ribose)polymerase activity prevents the recovery of C3H10T1/2 cells from oxidative stress. Biochim. Biophys. Acta (1996) 1312:1–7.
  • WELTIN D, MARCHAL J, DUFOUR P et al.: Effect of 6(51-1)-phenanthridinone, an inhibitor of poly(ADP-ribose)polymerase, on cultured tumor cells. °rico] Res. (1994) 6:399–403.
  • WELTIN D, HOLL V, HYUN JW etal. Effect of 6 (51–1)-phenanthridinone, a poly(ADP-ribose)polymerase inhibitor, and ionizing radiation on the growth of cultured lymphoma cells. Int. I Radiat. Biol. (1997) 72:685–692.
  • LI H, GOLDSTEIN BM: Carboxamide group conformation in the nicotinamide and thiazole-4-carboxamide rings: implication for enzyme binding. I Med. Chem. (1992) 35:3560–3567.
  • TAKAHASHI K, PIEPER AA, CROUL SE et al.: Post-treatment with an inhibitor of poly(ADP-ribose)polymerase attenuates cerebral damage in focal ischemia. Brain Res. (1999) 29:46–54.
  • SIMBULAN-ROSENTHAL MC, ROSENTHAL SD, LUO R et al: Inhibition of poly(ADP-ribose)polymerase activity is insufficient to induce tetraploidy. Nucleic Acid Res. (2001) 29:841–849.
  • ZHANG J, LAUTAR S, HUANG S et al: GPI 6150 prevents H202 cytotoxicity by inhibiting poly(ADP-ribose) polymerase. Biochem. Biophys. Res. Comm. (2000) 278:590–598.
  • OSHIMA T, PAVLICK lP, LAROUX FS. etal.: Regulation and distribution of MAdCAM-1 in endothelial cells in vitro. Am. I Physiol Cell physiol. (2001) 281:C1096–1105.
  • LAPLACA M, ZHANG J, RAGHUPATHI R: Pharmacological inhibition of poly(ADP-ribose) polymerase is neuroprotective following traumatic brain injury in rats. I Neurotrauma. (2001) 18:369–376.
  • 13th International Symposium on ADP-ribosylation. New York, USA. June (2001).
  • WHITE WA, ALMASSY AR, CALVERT AH eta].: Resistance-modifying agents. 9. Synthesis and biological properties of benzimidazole inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase. Med. Chem. (2000) 43:4084–4097.
  • SZABADOS E, LITERATI-NAGY P, FARKAS B et al: BGP-15, a nicotinic amidoxime derivate protecting heart from ischemia reperfusion injury through modulation of poly(ADP-ribose) polymerase. Biochem. Pharmacol (2000) 59:937–945.
  • MCDONALD CM, MOTA-FILIPE H, WRIGHT AJ etal.: Effects of 5-amino-isoquinolinone, a water-soluble, potent inhibitor of the activity of poly(ADP-ribose) polymerase on the organ injury and dysfunction caused by haemorrhagic shock. Br. J. Pharmacol (2000) 130:843–850.
  • LI J-H, SERDYUK L, FERRARIS VD et al.: Synthesis of substituted 5 HIPhenanthridin-6-ones as potent poly(ADP-ribose)polymerase-1 (PARP1) inhibitors. Bioorg. Med. Chem. Lett. (2001) 11:1687–1690.
  • RICE WG, SCHAEFFER CA, GRAHAM L et al.: The site of antiviral action of 3-nitrosobenzamide on the infectivity process of human immunodeficiency virus in human lymphocytes. Proc. Natl. Acad. Sci. USA (1993) 90:9721–9724
  • CHUANG AJ, KILLAM KF Jr, CHUANG RY et al.: Inhibition of the replication of native and 3'-azido-2',3'dideoxythymidine (AZT)-resistant simian immunodeficiency virus (SIV) by 3-nitrosobenzamide. FEBS Lett. (1993) 326:140–144.
  • RICE W, HILLYER CD, HARTEN B et al.: Induction of endonuclease-mediated apoptosis in tumor cells by C-nitroso-substituted ligands of poly(ADP-ribose) polymerase. Proc. Nati Acad. Li. USA (1992) 89:7703–7707.
  • RICE WC, SCHAEFFER CA, HARTEN B et al.: Inhibition of HIV-1 infectivity by zinc-ejecting aromatic C-nitroso compounds. Nature (1993) 361: 473–475.
  • Scrip (1996):2108–2123.
  • WELTIN D, PICARD V, AUPEIX K et al.: Immunosuppressive activities of 6(5H)-phenanthridinone, a new poly(ADP-ribose)polymerase inhibitor. Int. Immuriopharmacol. (1995) 4:265–71
  • PIEPER AA, BLACKSHAW S, CLEMENTS EE et al.: Poly(ADP-ribosyflation basally activated by DNA strand breaks reflects glutamate-nitric oxide neurotransmission. Proc. Natl. Acad Li. USA (2000) 97:1845–1850.
  • WALLIS RA, PANIZZON KL, HENRY D, WASTERLAIN CG: Neuroprotection against nitric oxide injury with inhibitors of ADP-ribosylation. Neuroreport (1993) 5(3):245–248.
  • KLAIDMAN LK, MUKHERJEE SK, HUTCHIN TP, ADAMS JD: Nicotinamide as a precursor for NAD+ prevents apoptosis in the mouse brain induced by tertiary-butylhydroperoxide. Neurosci lett (1996) 206(1):5–8.
  • ENDRES M, WANG ZQ, NAMURA S, WAEBER C, MOSKOWITZ MA: Ischemic brain injury is mediated by the activation of poly(ADP-ribose)polymerase. ?Cereb. Blood Flow Metab. (1997) 11:1143–1151.
  • TAKAHASHI K, GREENBERG JH, JACKSON P, MACLIN K, ZHANG J: Neuroprotective effects of inhibiting poly(ADP-ribose) synthetase on focal cerebral ischemia in rats. ?Cereb. Blood Flow Metab. (1997) 11:1137–1142.
  • TOKIME T, NOZAKI K, SUGINO T, KIKUCHI H, HASHIMOTO N, UEDA K: Enhanced poly(ADP-ribosyl)ation after focal ischemia in rat brain. ?Cereb. Blood Flow Metab. (1998) 18(9):991–997.
  • WALLIS RA, PANIZZON KL, GIRARD JM: Traumatic neuroprotection with inhibitors of nitric oxide and ADP-ribosylation. Brain Res. (1996) 710(1-2):169–177.
  • MAO J, PRICE DD, ZHU J, LU J, MAYER DJ: The inhibition of nitric oxide-activated poly(ADP-ribose) synthetase attenuates transsynaptic alteration of spinal cord dorsal horn neurons and neuropathic pain in the rat. Pain (1997) 72(3):355–366.
  • YAMAMOTO H, UCHIGATA Y, OKAMOTO H: Streptozotocin and alloxan induce DNA strand breaks and poly(ADP-ribose) synthetase in pancreatic islets. Nature (1981) 294(5838):284–286.
  • KROGER H, EHRLICH W, KLEWER M, GRATZ R, DIETRICH A, MIESEL R: The influence of antagonists of poly(ADP-ribose) metabolism on acetaminophen hepatotoxicity. Ceri. Pharmacol. (1996) 27(1):167–170.
  • BROADDUS VC, YANG L, SCAVO LM, ERNST JD, BOYLAN AM: Crocidolite asbestos induces apoptosis of pleural mesothelial cells: role of reactive oxygen species and poly(ADP-ribosyl) polymerase. Eriviron. Health Perspect. (1997) 105(Suppl 5):1147–1152.
  • HUDAK BB, TUFARIELLO J, SOKOLOWSKI J, MALONEY C, HOLM B: Inhibition of poly(ADP-ribose) polymerase preserves surfactant synthesis after hydrogen peroxide exposure. Am. j Physiol. (1995) 269(1)159–64.
  • THIEMERMANN C, BOWES J, MYINT FP, VANE JR: Inhibition of the activity of poly(ADP ribose) synthetase reduces ischemia-reperfusion injury in the heart and skeletal muscle. Proc. Nati Acad. Li. USA (1997) 94(2):679–683.
  • JIJON HB, CHURCHILL T, MALFAIR D et al.: Inhibition of poly(ADP-ribose) polymerase attenuates inflammation in a model of chronic colitis. Am. j Physiol. Castrointest Liver Physiol. (2000) 279(3):G641–651.
  • MARTIN DR, LEWINGTON AJ, HAMMERMAN MR, PADANILAM BJ: Inhibition of poly(ADP-ribose) polymerase attenuates ischemic renal injury in rats. Am. j Physiol. Regul. Integr. Comp. Physiol. (2000) 279(5):R1834–840.
  • LAM TT: The effect of 3-aminobenzamide, an inhibitor of poly-ADP-ribose polymerase, on ischemiaireperfusion damage in rat retina. Res. Commun. Mol. Pathol. Pharmacol. (1997) 95(3):241–252.
  • CHIANG SK, LAM TT: Post-treatment at 12 or 18 hours with 3-aminobenzamide ameliorates retinal ischemia-reperfusion damage. Invest. Ophthalmol. Vis. Li. (2000) 41(10):3210–3214.

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.